APA (7th ed.) Citation

E, B., E, C., J, M., E, G., L, D., & TJ, P. (2023). Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer: Overcoming Challenges in Genetic Testing and Clinical Considerations When Using Talazoparib. Clinical breast cancer, 23(5), 469. https://doi.org/10.1016/j.clbc.2023.04.006

Chicago Style (17th ed.) Citation

E, Brugioni, Cathcart-Rake E, Metsker J, Gustafson E, Douglass L, and Pluard TJ. "Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer: Overcoming Challenges in Genetic Testing and Clinical Considerations When Using Talazoparib." Clinical Breast Cancer 23, no. 5 (2023): 469. https://doi.org/10.1016/j.clbc.2023.04.006.

MLA (9th ed.) Citation

E, Brugioni, et al. "Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer: Overcoming Challenges in Genetic Testing and Clinical Considerations When Using Talazoparib." Clinical Breast Cancer, vol. 23, no. 5, 2023, p. 469, https://doi.org/10.1016/j.clbc.2023.04.006.